Completed PHASE2 INTERVENTIONAL 2-arm NCT02114892

Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

Sponsor: University of Guadalajara

Updated 9 times since 2017 Last updated: Aug 28, 2020 Started: Apr 30, 2012 Primary completion: Jul 31, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metabolic Syndrome X and is currently completed. University of Guadalajara leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2020 — Jan 2021 [monthly]

Completed PHASE2
Sep 2020 — Oct 2020 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

May 2020 — Sep 2020 [monthly]

Completed PHASE2
Nov 2019 — May 2020 [monthly]

Completed PHASE2
Jun 2018 — Nov 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Guadalajara

Data source: University of Guadalajara

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guadalajara, Mexico